PMID- 29494419
OWN - NLM
STAT- MEDLINE
DCOM- 20190415
LR  - 20190415
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 102
IP  - 10
DP  - 2018 Oct
TI  - ABO-incompatible Living Donor Liver Transplantation With Rituximab and Total
      Plasma Exchange Does Not Increase Hepatocellular Carcinoma Recurrence.
PG  - 1695-1701
LID - 10.1097/TP.0000000000002154 [doi]
AB  - BACKGROUND: ABO-incompatible (ABO-I) living donor liver transplantation (LDLT)
      has a high success rate. This study compares hepatocellular carcinoma (HCC)
      recurrence in ABO-I LDLT with that in ABO-compatible (ABO-C) LDLT and explores
      the effects of rituximab prophylaxis and total plasma exchange on HCC recurrence 
      after LDLT. METHODS: Two hundred forty patients with a diagnosis of HCC underwent
      LDLT between 2010 and 2015. Fifty-nine patients underwent ABO-I LDLT. RESULTS:
      Baseline, perioperative, and tumor characteristics did not vary between the 2
      groups. The 1-, 2-, and 3-year disease-free survival rates in the ABO-I LDLT and 
      ABO-C LDLT groups were 90.3%, 79.7%, and 73.3% and 86.7%, 79.0%, and 75.3%,
      respectively (P = 0.96). The overall patient survival rates for the same period
      in the ABO-I LDLT and ABO-C LDLT groups were 90.6%, 85.0%, and 81.9% and 88.0%,
      83.5%, and 82.5%, respectively (P = 0.77). Hepatocellular carcinoma recurrence
      after LDLT was associated with preoperative alpha-fetoprotein greater than 35
      ng/mL, increased tumor size, encapsulation, and microvascular invasion. ABO
      incompatibility was not related to HCC recurrence after LDLT. CONCLUSIONS:
      Hepatocellular carcinoma recurrence and patient survival in the ABO-I LDLT group 
      are comparable to those in the ABO-C LDLT group. Rituximab prophylaxis and total 
      plasma exchange do not increase HCC recurrence after LT.
FAU - Kim, Jong Man
AU  - Kim JM
AD  - Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, Seoul, Republic of Korea.
FAU - Kwon, Choon Hyuck David
AU  - Kwon CHD
AD  - Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, Seoul, Republic of Korea.
FAU - Joh, Jae-Won
AU  - Joh JW
AD  - Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, Seoul, Republic of Korea.
FAU - Han, Sangbin
AU  - Han S
AD  - Department of Anesthesiology and Pain Medicine, Samsung Medical Center,
      Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
FAU - Yoo, Jeejin
AU  - Yoo J
AD  - Statistics and Data Center, Samsung Medical Center, Seoul, Republic of Korea.
FAU - Kim, Kyunga
AU  - Kim K
AD  - Statistics and Data Center, Samsung Medical Center, Seoul, Republic of Korea.
FAU - Sinn, Dong Hyun
AU  - Sinn DH
AD  - Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of
      Medicine, Seoul, Republic of Korea.
FAU - Choi, Gyu-Seong
AU  - Choi GS
AD  - Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, Seoul, Republic of Korea.
FAU - Gerber, David A
AU  - Gerber DA
AD  - Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, 
      NC.
FAU - Egawa, Hiroto
AU  - Egawa H
AD  - Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical
      University, Tokyo, Japan.
FAU - Lee, Suk-Koo
AU  - Lee SK
AD  - Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, Seoul, Republic of Korea.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (ABO Blood-Group System)
RN  - 0 (Isoantibodies)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - ABO Blood-Group System/immunology
MH  - Adult
MH  - Aged
MH  - Allografts/immunology
MH  - Blood Group Incompatibility/immunology/*prevention & control
MH  - Carcinoma, Hepatocellular/epidemiology/*surgery
MH  - Disease-Free Survival
MH  - End Stage Liver Disease/surgery
MH  - Female
MH  - Graft Rejection/immunology/prevention & control
MH  - Humans
MH  - Isoantibodies/immunology
MH  - Liver/immunology
MH  - Liver Neoplasms/epidemiology/*surgery
MH  - Liver Transplantation/*adverse effects/methods
MH  - Living Donors
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*epidemiology
MH  - Plasma Exchange/*adverse effects
MH  - Preoperative Care/adverse effects/methods
MH  - Rituximab/*adverse effects
MH  - Survival Rate
MH  - Young Adult
EDAT- 2018/03/02 06:00
MHDA- 2019/04/16 06:00
CRDT- 2018/03/02 06:00
PHST- 2018/03/02 06:00 [pubmed]
PHST- 2019/04/16 06:00 [medline]
PHST- 2018/03/02 06:00 [entrez]
AID - 10.1097/TP.0000000000002154 [doi]
PST - ppublish
SO  - Transplantation. 2018 Oct;102(10):1695-1701. doi: 10.1097/TP.0000000000002154.